Thrombophilias: When Should We Test and How Does It Help?

ABSTRACT

Venous thromboembolism can be a life-threatening event, occurring in ~1 in 1000 adults annually. An underlying cause for thrombosis can now be identified in up to 80% of cases, including both inherited and acquired causes of thrombophilia. In fact, it is often a combination of these risk factors that leads to the development of thrombosis. Knowing what these risk factors are for an individual patient can help with decisions regarding duration of anticoagulation, and how best to prevent a recurrent event. This article reviews both the inherited and the acquired causes of thrombophilia, focusing on the clinical scenarios in which these disorders should be suspected and on how to appropriately test for them when clinically indicated. By the conclusion of this article, the clinician should be equipped with an algorithm of how to approach a patient with a thromboembolic event, from decisions regarding which thrombophilia tests to order to how the results of these tests affect patient management.

Venous thrombosis - inherited thrombophilia - acquired risk factors - duration of anticoagulation

REFERENCES

• 1 Cushman M. Epidemiology and risk factors for venous thrombosis.  Semin Hematol. 2007;  44 62-69
• 2 Bauer K A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications.  Ann Intern Med. 2001;  135 367-373
• 3 Perry S L, Ortel T L. Clinical and laboratory evaluation of thrombophilia.  Clin Chest Med. 2003;  24 153-170
• 4 Moll S. Thrombophilias: practical implications and testing caveats.  J Thromb Thrombolysis. 2006;  21 7-15
• 5 Lapostolle F, Surget V, Borron S W et al.. Severe pulmonary embolism associated with air travel.  N Engl J Med. 2001;  345 779-783
• 6 Prandoni P, Lensing A W, Buller H R et al.. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.  N Engl J Med. 1992;  327 1128-1133
• 7 Lochhead P, Miedzybrodzka Z. The essential role of genetic counseling in inherited thrombophilia.  Semin Hematol. 2007;  44 126-129
• 8 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.  Blood. 1998;  92 2353-2358
• 9 Simioni P, Tormene D, Prandoni P et al.. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study.  Blood. 2002;  99 1938-1942
• 10 Sanson B J, Simioni P, Tormene D et al.. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study.  Blood. 1999;  94 3702-3706
• 11 Mannucci P M. Genetic hypercoagulability: prevention suggests testing family members.  Blood. 2001;  98 21-22
• 12 Tormene D, Simioni P, Prandoni P et al.. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study.  Blood. 2002;  100 2403-2405
• 13 Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet. 1993;  342 1503-1506
• 14 de Visser M C, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood. 1999;  93 1271-1276
• 15 Ridker P M, Miletich J P, Stampfer M J et al.. Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation. 1995;  92 2800-2802
• 16 Turkstra F, Karemaker R, Kuijer P M, Prins M H, Buller H R. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?.  Thromb Haemost. 1999;  81 345-348
• 17 Simioni P, Prandoni P, Lensing A W et al.. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med. 1997;  336 399-403
• 18 Eichinger S, Pabinger I, Stumpflen A et al.. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.  Thromb Haemost. 1997;  77 624-628
• 19 Keijzer M B, den Heijer M, Blom H J et al.. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis.  Thromb Haemost. 2002;  88 723-728
• 20 Ho W K, Hankey G J, Quinlan D J, Eikelboom J W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.  Arch Intern Med. 2006;  166 729-736
• 21 Ridker P M, Goldhaber S Z, Danielson E et al.. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  348 1425-1434
• 22 Kearon C, Ginsberg J S, Kovacs M J et al.. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  349 631-639
• 23 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
• 24 Smirnov M D, Safa O, Esmon N L, Esmon C T. Inhibition of activated protein C anticoagulant activity by prothrombin.  Blood. 1999;  94 3839-3846
• 25 Butenas S, van't Veer C, Mann K G. “Normal” thrombin generation.  Blood. 1999;  94 2169-2178
• 26 Miles J S, Miletich J P, Goldhaber S Z, Hennekens C H, Ridker P M. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.  J Am Coll Cardiol. 2001;  37 215-218
• 27 Simioni P, Prandoni P, Lensing A W et al.. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.  Blood. 2000;  96 3329-3333
• 28 Eichinger S, Minar E, Hirschl M et al.. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.  Thromb Haemost. 1999;  81 14-17
• 29 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.  Br J Haematol. 2001;  113 630-635
• 30 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.  Thromb Haemost. 1999;  81 684-689
• 31 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med. 1999;  341 801-806
• 32 Koster T, Rosendaal F R, Briet E et al.. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study).  Blood. 1995;  85 2756-2761
• 33 Broekmans A W. Hereditary protein C deficiency.  Haemostasis. 1985;  15 233-240
• 34 Adachi T. Protein S and congenital protein S deficiency: the most frequent congenital thrombophilia in Japanese.  Curr Drug Targets. 2005;  6 585-592
• 35 De Stefano V, Simioni P, Rossi E et al.. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S.  Haematologica. 2006;  91 695-698
• 36 Prandoni P, Noventa F, Ghirarduzzi A et al.. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients.  Haematologica. 2007;  92 199-205
• 37 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors.  Arterioscler Thromb Vasc Biol. 1996;  16 742-748
• 38 Martinez J. Congenital dysfibrinogenemia.  Curr Opin Hematol. 1997;  4 357-365
• 39 Tsai A W, Cushman M, Rosamond W D et al.. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).  Am J Med. 2002;  113 636-642
• 40 Nossent A Y, Eikenboom J C, Bertina R M. Plasma coagulation factor levels in venous thrombosis.  Semin Hematol. 2007;  44 77-84
• 41 den Heijer M, Koster T, Blom H J et al.. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med. 1996;  334 759-762
• 42 Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis.  Semin Hematol. 2007;  44 70-76
• 43 den Heijer M, Willems H P, Blom H J et al.. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial.  Blood. 2007;  109 139-144
• 44 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.  Lancet. 1995;  345 152-155
• 45 Christiansen S C, Cannegieter S C, Koster T, Vandenbroucke J P, Rosendaal F R. Thrombophilia, clinical factors, and recurrent venous thrombotic events.  JAMA. 2005;  293 2352-2361
• 46 Kyrle P A, Minar E, Hirschl M et al.. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.  N Engl J Med. 2000;  343 457-462
• 47 Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.  Br J Haematol. 2006;  134 227-232
• 48 van Hylckama Vlieg A, van der Linden I K, Bertina R M, Rosendaal F R. High levels of factor IX increase the risk of venous thrombosis.  Blood. 2000;  95 3678-3682
• 49 Weltermann A, Eichinger S, Bialonczyk C et al.. The risk of recurrent venous thromboembolism among patients with high factor IX levels.  J Thromb Haemost. 2003;  1 28-32
• 50 Meijers J C, Tekelenburg W L, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis.  N Engl J Med. 2000;  342 696-701
• 51 von Depka M, Nowak-Gottl U, Eisert R et al.. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.  Blood. 2000;  96 3364-3368
• 52 Sartori M T, Patrassi G M, Theodoridis P, Perin A, Pietrogrande F, Girolami A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds.  Blood Coagul Fibrinolysis. 1994;  5 889-893
• 53 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
• 54 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 55 Ginsberg J S, Wells P S, Brill-Edwards P et al.. Antiphospholipid antibodies and venous thromboembolism.  Blood. 1995;  86 3685-3691
• 56 Vila P, Hernandez M C, Lopez-Fernandez M F, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.  Thromb Haemost. 1994;  72 209-213
• 57 Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G R. The management of thrombosis in the antiphospholipid-antibody syndrome.  N Engl J Med. 1995;  332 993-997
• 58 Crowther M A, Ginsberg J S, Julian J et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
• 59 Finazzi G, Marchioli R, Brancaccio V et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).  J Thromb Haemost. 2005;  3 848-853
• 60 Khorana A A, Francis C W, Culakova E, Fisher R I, Kuderer N M, Lyman G H. Thromboembolism in hospitalized neutropenic cancer patients.  J Clin Oncol. 2006;  24 484-490
• 61 Heit J A, O'Fallon W M, Petterson T M et al.. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.  Arch Intern Med. 2002;  162 1245-1248
• 62 Blom J W, Vanderschoot J P, Oostindier M J, Osanto S, van der Meer F J, Rosendaal F R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.  J Thromb Haemost. 2006;  4 529-535
• 63 Schafer A I. Thrombocytosis.  N Engl J Med. 2004;  350 1211-1219
• 64 Schafer A I. Thrombocytosis and thrombocythemia.  Blood Rev. 2001;  15 159-166
• 65 Gruppo Italiano Studio Policitemia . Polycythemia vera: the natural history of 1213 patients followed for 20 years.  Ann Intern Med. 1995;  123 656-664
• 66 Valla D, Casadevall N, Huisse M G et al.. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders.  Gastroenterology. 1988;  94 1063-1069
• 67 De Stefano V, Teofili L, Leone G, Michiels J J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.  Semin Thromb Hemost. 1997;  23 411-418
• 68 Baxter E J, Scott L M, Campbell P J et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet. 2005;  365 1054-1061
• 69 Primignani M, Barosi G, Bergamaschi G et al.. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.  Hepatology. 2006;  44 1528-1534
• 70 Colaizzo D, Amitrano L, Tiscia G L et al.. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.  J Thromb Haemost. 2007;  5 55-61
• 71 Sagripanti A, Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome.  Nephron. 1995;  70 271-281
• 72 Bernstein C N, Blanchard J F, Houston D S, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.  Thromb Haemost. 2001;  85 430-434
• 73 Friederich P W, Sanson B J, Simioni P et al.. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.  Ann Intern Med. 1996;  125 955-960
• 74 Gerhardt A, Scharf R E, Zotz R B. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium.  Thromb Haemost. 2003;  90 77-85
• 75 Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Oral contraceptives, hormone replacement therapy and thrombosis.  Thromb Haemost. 2001;  86 112-123
• 76 Parkin L, Skegg D C, Wilson M, Herbison G P, Paul C. Oral contraceptives and fatal pulmonary embolism.  Lancet. 2000;  355 2133-2134
• 77 Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study.  Contraception. 2002;  65 187-196
• 78 Watson H G. Sex hormones and thrombosis.  Semin Hematol. 2007;  44 98-105
• 79 Cushman M, Kuller L H, Prentice R et al.. Estrogen plus progestin and risk of venous thrombosis.  JAMA. 2004;  292 1573-1580
• 80 Fisher B, Costantino J P, Wickerham D L et al.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst. 1998;  90 1371-1388
• 81 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.  J Clin Oncol. 1991;  9 286-294
• 82 Lycette J L, Luoh S W, Beer T M, Deloughery T G. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.  Breast Cancer Res Treat. 2006;  99 249-255
• 83 Rajkumar S V. Thalidomide therapy and deep venous thrombosis in multiple myeloma.  Mayo Clin Proc. 2005;  80 1549-1551
• 84 Arepally G M, Ortel T L. Clinical practice: heparin-induced thrombocytopenia.  N Engl J Med. 2006;  355 809-817
• 85 Geerts W H, Code K I, Jay R M, Chen E, Szalai J P. A prospective study of venous thromboembolism after major trauma.  N Engl J Med. 1994;  331 1601-1606
• 86 Tsai A W, Cushman M, Rosamond W D, Heckbert S R, Polak J F, Folsom A R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.  Arch Intern Med. 2002;  162 1182-1189
• 87 O'Brien A E, Tate G M, Shiach C. Evaluation of protein C and protein S levels during oral anticoagulant therapy.  Clin Lab Haematol. 1998;  20 245-252
• 88 Buller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 401S-428S
• 89 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 90 Palareti G, Cosmi B, Legnani C et al.. D-dimer testing to determine the duration of anticoagulation therapy.  N Engl J Med. 2006;  355 1780-1789
• 91 Prandoni P, Lensing A W, Prins M H et al.. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.  Ann Intern Med. 2002;  137 955-960